Medicare Enrolled
Dr. Nandini Ignatius, MD
Hematology & Oncology · Newark, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Ignatius from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ignatius?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Ignatius
Dr. Nandini Ignatius is a hematology & oncology specialist in Newark, NJ, with 16 years of NPI registration. Based on federal Medicare data, Dr. Ignatius performed 66,583 Medicare services across 2,557 unique beneficiaries.
Between the years covered by Open Payments, Dr. Ignatius received a total of $9,867 from 90 pharmaceutical and/or device companies across 621 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Ignatius is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years in practice
▲ Top 17% volume in NJ
$9,867 industry payments
Medicare Practice Summary
Medicare Utilization ↗66,583
Medicare services
Top 17% in NJ for hematology & oncology
2,557
Unique beneficiaries
$9
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~4,161 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
41,500 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 8,400 | $19 | $62 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
4,340 | $6 | $47 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
3,240 | $6 | $28 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,531 | $8 | $32 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,492 | $8 | $18 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,082 | $0 | $1 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
598 | $99 | $231 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
558 | $99 | $232 |
| Pegfilgrastim-cbqv injection An injection of pegfilgrastim-cbqv, a biosimilar medication, administered at a dose of 0.5 mg. |
480 | $109 | $900 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
464 | $25 | $128 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
429 | $146 | $307 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
388 | $12 | $82 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
289 | $55 | $264 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
253 | $114 | $580 |
| Injection, granisetron hydrochloride, 100 mcg | 240 | $0 | $19 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
229 | $145 | $418 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
215 | $1 | $13 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
182 | $1 | $6 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
173 | $63 | $199 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
137 | $13 | $97 |
| New patient office visit, complex (60-74 min) | 117 | $173 | $441 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
88 | $25 | $146 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
47 | $77 | $246 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
40 | $1 | $16 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
37 | $73 | $154 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
34 | $57 | $323 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.6% high complexity
90.5% medium
7.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$9,867
Total received (2018-2024)
Avg $1,410/year across 7 years
Top 28% in NJ for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
90
Companies
621
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,700 (98.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$167 (1.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$954
2023
$1,937
2022
$2,525
2021
$1,560
2020
$1,140
2019
$1,105
2018
$646
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$79
Daiichi Sankyo Inc.
$78
E.R. Squibb & Sons, L.L.C.
$49
Eisai Inc.
$49
PUMA BIOTECHNOLOGY, INC.
$46
Bayer Healthcare Pharmaceuticals Inc.
$45
Adaptive Biotechnologies Corporation
$41
SpringWorks Therapeutics, Inc.
$38
Novartis Pharmaceuticals Corporation
$34
Mirati Therapeutics, Inc.
$34
PFIZER INC.
$32
Astellas Pharma US Inc
$32
Incyte Corporation
$31
SOBI, INC
$30
Aveo Pharmaceuticals, Inc.
$29
Dendreon Pharmaceuticals LLC
$29
TAIHO ONCOLOGY, INC.
$27
Janssen Pharmaceuticals, Inc
$23
Stemline Therapeutics Inc.
$21
SERVIER PHARMACEUTICALS LLC
$20
Apellis Pharmaceuticals, Inc.
$20
ARRAY BIOPHARMA INC
$19
Pharmacosmos Therapeutics Inc.
$18
Celgene Corporation
$18
Genentech USA, Inc.
$17
Azurity Pharmaceuticals, Inc.
$17
Merck Sharp & Dohme LLC
$17
ABBVIE INC.
$17
Octapharma USA, Inc.
$16
Gilead Sciences, Inc.
$15
Blueprint Medicines Corporation
$13
Top 3 companies account for 21.6% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,141
E.R. Squibb & Sons, L.L.C.
$915
Incyte Corporation
$422
Janssen Biotech, Inc.
$414
Celgene Corporation
$406
GENZYME CORPORATION
$396
Eisai Inc.
$308
Amgen Inc.
$300
Seagen Inc.
$298
PFIZER INC.
$294
Bayer HealthCare Pharmaceuticals Inc.
$281
Merck Sharp & Dohme LLC
$256
AstraZeneca Pharmaceuticals LP
$253
Daiichi Sankyo Inc.
$232
Lilly USA, LLC
$224
Astellas Pharma US Inc
$222
Kite Pharma, Inc.
$194
Merck Sharp & Dohme Corporation
$155
Stemline Therapeutics Inc.
$142
EMD Serono, Inc.
$131
Genentech USA, Inc.
$119
ABBVIE INC.
$114
Takeda Pharmaceuticals U.S.A., Inc.
$111
ARRAY BIOPHARMA INC
$108
Puma Biotechnology, Inc.
$102
Gilead Sciences, Inc.
$101
GlaxoSmithKline, LLC.
$86
Boehringer Ingelheim Pharmaceuticals, Inc.
$84
Bayer Healthcare Pharmaceuticals Inc.
$81
Kyowa Kirin, Inc.
$75
PUMA BIOTECHNOLOGY, INC.
$73
Coherus Biosciences Inc.
$71
Adaptive Biotechnologies Corporation
$60
EISAI INC.
$57
GE HEALTHCARE
$56
Pharmacosmos Therapeutics Inc.
$55
G1 Therapeutics, Inc.
$52
Rigel Pharmaceuticals, Inc.
$51
Genmab U.S., Inc.
$49
Mirati Therapeutics, Inc.
$48
SOBI, INC
$47
Myovant Sciences Inc.
$46
Ipsen Biopharmaceuticals, Inc
$46
Pharmacyclics LLC, An AbbVie Company
$45
TAIHO ONCOLOGY, INC.
$44
Foundation Medicine, Inc.
$44
Blueprint Medicines Corporation
$43
Jazz Pharmaceuticals Inc.
$42
AbbVie Inc.
$41
SpringWorks Therapeutics, Inc.
$38
BeiGene USA, Inc.
$38
SERVIER PHARMACEUTICALS LLC
$36
AbbVie, Inc.
$36
Apellis Pharmaceuticals, Inc.
$34
Octapharma USA, Inc.
$32
Karyopharm Therapeutics Inc.
$32
Exelixis Inc.
$31
AVEO Pharmaceuticals, Inc.
$30
Epizyme, Inc.,
$30
Aveo Pharmaceuticals, Inc.
$29
Dendreon Pharmaceuticals LLC
$29
MorphoSys, US Inc.
$29
Seattle Genetics, Inc.
$29
Clovis Oncology, Inc.
$28
Acceleron Pharma, Inc.
$28
Regeneron Healthcare Solutions, Inc.
$28
Taiho Oncology, Inc.
$27
Mylan Institutional Inc.
$27
Spectrum Pharmaceuticals Inc.
$23
Janssen Pharmaceuticals, Inc
$23
Agios Pharmaceuticals, Inc.
$20
Aadi Bioscience, Inc.
$17
Azurity Pharmaceuticals, Inc.
$17
Alexion Pharmaceuticals, Inc.
$17
Teva Pharmaceuticals USA, Inc.
$16
PharmaEssentia USA Corporation
$15
SANOFI-AVENTIS U.S. LLC
$15
TESARO, Inc.
$15
Horizon Therapeutics plc
$15
JAZZ PHARMACEUTICALS INC.
$15
ImmunoGen, Inc.
$15
Sirtex Medical Inc
$14
Epizyme, Inc.
$14
Endo Pharmaceuticals Inc.
$14
Global Blood Therapeutics, Inc.
$14
Pharmacyclics LLC, an AbbVie Company
$14
EUSA Pharma (US) LLC
$14
Dova Pharmaceuticals
$14
Helsinn Therapeutics (U.S.), Inc.
$14
ADC Therapeutics America, Inc.
$12
Top 3 companies account for 25.1% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · AYVAKIT · Abraxane · Alecensa · Aliqopa · Avastin · BENDEKA · BESREMI · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Blincyto · CALQUENCE · COSELA · CYRAMZA · Cabometyx · Columvi · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ENJAYMO · ERBITUX · ERLEADA · Elahere · Empaveli · Enhertu · Epkinly · FOTIVDA · FOUNDATIONONE · Fulphila · Fyarro · GAVRETO · GILOTRIF · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INQOVI · Imbruvica · JADENU · JAKAFI · JEMPERLI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · NASCOBAL · NERLYNX · NINLARO · Nerlynx · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OGSIVEO · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Onivyde · Orserdu · PADCEV · PANZYGA · PEMAZYRE · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · PYRUKYND · Padcev · Perjeta · Pomalyst · Poteligeo · REBLOZYL · RETEVMO · ROLVEDON · RYBREVANT · Reblozyl · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · Stivarga · Sylvant · TAFINLAR · TAGRISSO · TASIGNA · TAZVERIK · TECVAYLI · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tavalisse · Tazverik · Tibsovo · Trodelvy · ULTOMIRIS · Udenyca · VALCHLOR · VENCLEXTA · VERZENIO · VIVIMUSTA · VOTRIENT · VYXEOS · Vectibix · Venclexta · Vitrakvi · XALKORI · XARELTO · XGEVA · XPOVIO · XTANDI · Xofigo · Xospata · Xtandi · ZEJULA · ZEPZELCA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (98%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
681
Per 100K population
79.7
County median income
$76,712
Nearest hospital
THE UNIVERSITY HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Ignatius is a mixed practice specialist, with above-average Medicare volume (top 17% in NJ), with low-engagement industry engagement, with 16 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Ignatius experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Ignatius performed 41,500 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Ignatius receive payments from pharmaceutical companies?
Yes. Dr. Ignatius received a total of $9,867 from 90 companies across 621 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ignatius's costs compare to other hematology & oncology specialists in Newark?
Dr. Ignatius's average Medicare payment per service is $9. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ignatius) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Newark
Browse hematology & oncology specialists in Newark ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NJ
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NJ
Which NJ hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology